



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/009,328	12/04/2001	Preeti Lal	PF-0709 USN	6996

7590 12/10/2002

Incyte Genomics Inc
Legal Department
3160 Porter Drive
Palo Alto, CA 95304

[REDACTED] EXAMINER

BASKAR, PADMAVATHI

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1645

DATE MAILED: 12/10/2002

5

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/009,328	LAL ET AL.	
	Examiner	Art Unit	
	Padmavathi v Baskar	1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-11, 13, 15-17, 19, 22, 26 and 27 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-11, 13, 17, 19, 22, 26, and 27 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some *
 - c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

Art Unit: 1645

RESTRICTION

1. Applicant's amendment filed on 12/04/01 has been entered. Claims 12, 14, 18, 20; 21,23,24,25 and 28-230 have been canceled. Claims 1-11, 13,15- 17, 19, 22, 26, and 27 are pending in the application.

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-2,16, 17, 9 and 19, drawn to polypeptide, pharmaceutical composition and a method for screening compounds for effectiveness as an agonist using polypeptide. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Group II, claims 3-8, and 11 drawn to DNA, vector and host cell. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Group III, claim 10 drawn to an antibody. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Group IV, claim 13 drawn to a method for detecting target polynucleotide by hybridization. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Art Unit: 1645

Group V, claim 15 drawn to a method for detecting target polynucleotide by PCR. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Group VI, claim 22 drawn to a method for screening compounds for effectiveness as an antagonist using polypeptide. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Group VII, claim 26 drawn to a method of screening for compounds that modulates the activity of the polypeptide. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

Group VIII, claim 27 drawn to a method for screening compounds for effectiveness in altering expression of a target polynucleotide. Further restriction to one SEQ.ID.NO required (see paragraph # 3).

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is directed to a polypeptide, method of making and a method of use. The special technical feature is the polypeptide, which is made up of amino acids. Groups II-III are drawn to structurally different products such as nucleic acids and antibodies which do not require each other for their practice and do not share the same or a corresponding technical feature. The Group IV-VIII inventions are drawn to different methods having different goals, method steps and starting materials, which do not require each other for their practice and do not share the

Art Unit: 1645

same or a corresponding technical feature. Note that PCT Rule 13.2 does not provide for multiple products or methods within a single application since Group I includes polypeptide, which is the first product, method of making and method of use. Since the special technical feature of the Group I invention is not present in the Group II-VIII claims, and the special technical features of the Group II-VIII inventions are not present in the Group I claims, unity of invention is lacking.

DISTINCT INVENTIONS

3. For each group of inventions I-VIII above, restriction to one of the following SEQ.ID.NO is also required under 35 U.S.C. 121 and 372. Therefore, election is required of one of inventions I – VIII and one of SEQ ID NO: 1 – 4, 6-10, 12-36, 38-39, 41-43 and 44-53, 55-79, 81-86.

Inventions SEQ ID NO: 1 – 4, 6-10, 12-36, 38-39, 41-43 and Inventions SEQ.ID.NO: 44-53, 55-79, 81-86 are not so linked as to under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

SEQ ID NO: 1 – 4, 6-10, 12-36, 38-39, 41-43 and 44-53, 55-79, 81-86 represent structurally different polypeptides and the polynucleotides encoding them. Therefore, where structural identity is required, such as for hybridization or expression, the different sequences have different effects. Thus, each sequence is unique and patentably distinct since each sequence has a different structure with specific amino acid or nucleic acid and is identified by a specific SEQ.ID.NO and thus lacks the same or corresponding special technical features. Applicant is required under Restriction is required under 35 U.S.C. 121 and 372 to elect a single disclosed SEQ.ID.NO from any group elected.

Art Unit: 1645

4. Applicant is required, in reply to this action, to elect a group and one sequence and identify the SEQ.ID.NO to which the claims shall be restricted. The reply must also identify the claims readable on the elected invention, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Padmavathi v Baskar whose telephone number is (703) 308-8886. The examiner can normally be reached on M-F (6:30A.M-4: 00 P.M.) First Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (703) 308-3909. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

P. Baskar Ph.D.

12/2/02

L.R.S.
LYNETTE R. P. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600